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Abstract It has been commonly assumed that Zika virus (ZIKV) infection confers long-term
protection against reinfection, preventing ZIKV from re-emerging in previously affected areas for
several years. However, the long-term immune response to ZIKV following an outbreak remains
poorly documented. We compared results from eight serological surveys before and after known
ZIKV outbreaks in French Polynesia and Fiji, including cross-sectional and longitudinal studies. We
found evidence of a decline in seroprevalence in both countries over a two-year period following
first reported ZIKV transmission. This decline was concentrated in adults, while high seroprevalence
persisted in children. In the Fiji cohort, there was also a significant decline in neutralizing antibody
titres against ZIKV, but not against dengue viruses that circulated during the same period.
Introduction
Zika virus (ZIKV), a Flavivirus primarily transmitted to humans by Aedes mosquitoes, was first
reported in the Pacific region on Yap island (Federated States of Micronesia) in 2007 (Duffy et al.,
2009). Six years later, there was a large ZIKV outbreak in French Polynesia (Cao-Lormeau et al.,
2014) where an estimated 11.5% of the population visited healthcare facilities with clinical symptoms
suggestive of ZIKV infection (Kucharski et al., 2016). Since then the virus has spread across the
Pacific region (Musso et al., 2014), including to Fiji where cases of ZIKV infection were first detected
in July 2015 (World Health Organisation, 2015). The same year, cases of ZIKV infection in Latin
America were reported for the first time (Zammarchi et al., 2015). From February 1 to November
18, 2016, due to its rapid spread and association with birth defects, microcephaly in newborns and
Guillain-Barre´ syndrome in adults (Cao-Lormeau et al., 2016) the WHO declared ZIKV a Public
Health Emergency of International Concern (World Health Organisation, 2016). At the end of
2016, outbreaks had declined in most of the countries recently affected (O’Reilly et al., 2018). How-
ever, ZIKV was still circulating in 2018 in several countries, including Fiji and Tonga in the Pacific
region (World Health Organisation, 2019).
In countries with known ZIKV outbreaks, the few serological surveys that have been published
found a high level of ZIKV seroprevalence following the outbreak. In French Polynesia, a population-
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representative cross-sectional serological survey at the end of the outbreak in 2014 found a sero-
prevalence of 49% (Aubry et al., 2017). In Martinique, a study of blood donors showed a post-out-
break seroprevalence of 42% in 2015 (Gallian et al., 2017). In Salvador, Northeastern Brazil, a
serosurvey in 2016 of prospectively sampled individuals including microcephaly and non-microceph-
aly pregnancies, HIV-infected patients, tuberculosis patients, and university staff, found a post-out-
break seroprevalence of 63% (Netto et al., 2017). Another study in Salvador, conducted in a long-
term health cohort, also found a post-outbreak seroprevalence of 63% (Rodriguez-Barraquer et al.,
2019). Finally, in paediatric and household cohort studies in Managua, Nicaragua, ZIKV seropreva-
lence was estimated to be 46% in households following the outbreak in 2016 (Zambrana et al.,
2018).
It has been suggested that infection with ZIKV confers immunity that lasts several years; if so, the
high level of seroprevalence in affected countries may reflect sufficient herd immunity for the current
ZIKV epidemic to be over in many locations, with the virus unable to re-emerge for decades to come
(Kucharski et al., 2016; O’Reilly et al., 2018; Netto et al., 2017; Ferguson et al., 2016). Recent
evidence suggests that neutralizing antibodies can distinguish between ZIKV and dengue virus
(DENV) – a closely related Flavivirus – and that the immune response following ZIKV infection can
persist over a year (Montoya et al., 2018; Griffin et al., 2019). It has also been suggested that pri-
mary ZIKV infection may confer protective immunity (Osuna et al., 2016). However, ZIKV serosurveys
conducted at the end of the outbreak in French Polynesia and 18 months later found a drop in sero-
prevalence in the Society Islands, the archipelago where over 85% of the inhabitants of French Poly-
nesia reside (Aubry et al., 2017). Therefore, the long-term antibody response following a ZIKV
outbreak remains unclear.
Here, we explore short- and long-term seroprevalence against ZIKV as well as neutralizing
responses against ZIKV following two ZIKV outbreaks in the Pacific region. We compared results
from five serological surveys in the Society Islands, French Polynesia, over a seven-year period, and
three serial serological surveys in the same cohort of individuals in Central Division, Fiji, over a four-
year period. These surveys span the pre- and post- outbreak period in each country, allowing us to
examine temporal changes in antibody responses following a ZIKV outbreak.
Results
In French Polynesia, seroprevalence of IgG antibodies against domain III of the ZIKV envelope glyco-
protein in blood donors recruited before October 2013 was <1% (0.3–2%), which confirmed that the
virus had not previously circulated in the population (Table 1). Analysis of samples collected in the
eLife digest Since the Zika virus first emerged in the Pacific Islands in 2007, it has caused many
outbreaks in the Pacific and Latin America. Some scientists thought that after exposure to the virus
people would develop long-term immunity to it, reducing the number of outbreaks in the future.
Several studies supported this idea. These studies showed that many people recently infected with
Zika developed antibodies in their blood that might protect them from becoming ill during future
outbreaks. But it was not clear how long this protection would last.
To better understand how immunity to the Zika virus changes over time, Henderson, Aubry et al.
combined data from eight surveys that collected blood samples at different time points during Zika
outbreaks in French Polynesia and Fiji. The analysis showed that the proportion of people with
detectable antibodies against the Zika virus increased in both countries after the outbreaks. In
children these immune responses persisted for years, but antibody levels declined over time in
adults. By contrast, antibodies to the closely related dengue virus did not wane over time in
individuals tested for both viruses in Fiji in 2013, 2015 and 2017.
The data suggest that immunity against the Zika virus may not last as long as previously thought,
which could affect the chances of future outbreaks. The findings may also have implications for
researchers studying the virus, because the number of people with antibodies against the virus is not
a good estimate of how many people were initially infected. More studies are needed to understand
immunity to Zika virus over time and how it may affect future outbreaks.
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general population of the Society Islands of French Polynesia after the emergence of ZIKV showed a
decrease in ZIKV seroprevalence from 37% (26–47%) to 22% (16–28%) between February-March
2014 and September-November 2015 (chi-squared test, p=0.03). In Fiji, analysis of the serum sam-
ples serially collected from a cohort of participants in the Central Division showed an increase in
ZIKV seroprevalence from 6.3% (3.3–11%) in October-November 2013 to 24% (18–31%) in Novem-
ber 2015 (chi-squared test, p<0.0001), and then a decrease to 12% (7.9–18%) by June 2017 (chi-
squared test, p=0.005). In this cohort, based on IgG results tested by microsphere immunoassay
(MIA), 6 of the 189 participants seroconverted (from negative to positive) and 28 seroreverted (from
positive to negative) to ZIKV between 2015 and 2017 (McNemar’s test, p=0.0003).
To investigate possible factors influencing the decline in seroprevalence, we compared the sero-
prevalence profiles in children (defined as 16 years) and adults (>16 years) in both settings (Table 1
and Figure 1). In French Polynesia, although ZIKV seroprevalence declined in the general population
from the Society Islands over 18 months, there was no evidence of a significant decline in seropreva-
lence in two serosurveys conducted four years apart in schoolchildren aged 6 to 16 years, with 66%
(60–71%) positive in 2014 and 64% (58–69%) in 2018 (chi-squared test, p=0.6) (Table 1). When strati-
fying the general population from the Society Islands by age (16 years and >16 years), there was a
decline in adults in the two consecutive cross-sectional studies conducted in 2014 and 2015, from
35.4% (22.2–50.5%) to 21.3% (18.2–24.5%) (Figure 1). A decline in adults was still observed, albeit
with larger uncertainty, when the two datasets were standardised according to the age distribution
of the population, with age-adjusted seroprevalence decreasing from 32.0% (16.7–62.1%) to 26.0%
(20.1–33.9%) (Table 2).
In Fiji, in the subset of individuals who were aged over 16 years (n = 122), there was a decrease in
seroprevalence by MIA from 24% (17–33%) in 2015 to 7.3% (3.4–13%) 2017 (Figure 1). There were
two seroconversions in the collected samples over this period but 23 seroreversions (McNemar’s
test, p<0.0001) (Table 3). In contrast seroprevalence in participants aged 16 and under (n = 67)
remained relatively stable over this period (Figure 1), with four seroconversions and five serorever-
sions (McNemar’s test, p=1) (Table 3).
Table 1. Seroprevalence of ZIKV among participants in five serological surveys in French Polynesia and three serological surveys in
Fiji, conducted between July 2011 and June 2018.
Date Country
Population and assay
used
Age range
(median)
Total no. seropositive/total no.
tested
Seroprevalence %
[95% CI]
French Polynesia - General Population
Jul 2011-Oct
2013
Society Islands, French
Polynesia
Blood donors, ELISA 18–75 (36) 5/593 0.8 [0.3–2.0]
Nov 2013 First confirmed local transmission of ZIKV in French Polynesia
Feb-Mar 2014 Society Islands, French
Polynesia
General, ELISA 13–77 (47) 18/49 37 [26-47]*
Sep-Nov 2015 Society Islands, French
Polynesia
General, MIA 4–88 (43) 154/700 22 [16-28]*
French Polynesia - schoolchildren
May-Jun 2014 Society Islands, French
Polynesia
School children,
ELISA
6–16 (11) 312/476 66 [60-71]*
Jun-2018 Society Islands, French
Polynesia
School children,
MIA
6–16 (11) 291/457 64 [58-69]*
Fiji
Oct-Nov 2013 Central Division, Fiji General, MIA 2–78 (24) 12/189 6.3 [3.3–11]
Jul 2015 First confirmed local transmission of ZIKV in Fiji
Nov-2015 Central Division, Fiji General, MIA 4–80 (26) 45/189 24 [18-31]
Jun-2017 Central Division, Fiji General, MIA 6–82 (28) 23/189 12 [7.9–18]
* CIs were calculated taking into account the cluster sampling design (Aubry et al., 2017) and using the Fisher exact test.
MIA – microsphere immunoassay.
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Figure 1. Dynamics of ZIKV seroprevalence following outbreaks in Fiji and French Polynesia. (A) Seroprevalence by MIA in Fiji. Red, seroprevalence and
95% confidence intervals for children (aged 16 years). Orange, seroprevalence and 95% confidence intervals for adults (aged >16 years). Solid lines,
trends in data collected from the same individuals. Dotted line indicates the first confirmed ZIKV case. (B) Epidemiological dynamics in Fiji between
2013 and 2018. Coloured bars show number of PCR-confirmed samples of different DENV serotypes and ZIKV in Fiji; black lines show reported
prolonged fever in Fiji from the Pacific Syndromic Surveillance System (World Health Organization, 2019). There was a major outbreak of DENV-3
outbreak in 2013–14 (Kucharski et al., 2018a) with a smaller DENV-2 outbreak in early 2017 (Aubry et al., 2019). (C) Seroprevalence by MIA in French
Polynesia. Dashed lines, trends in seroprevalence between population representative cross-sectional surveys. Note that the pre-outbreak samples were
collected between July 2011 and October 2013; for brevity, the latest possible collection date is used in the plot. (D) Epidemiological dynamics in
French Polynesia between 2013 and 2018. Solid black line shows reported symptomatic dengue cases; dashed lines showed reported symptomatic Zika
cases. In French Polynesia, between the sampling periods, there were no reported DENV outbreaks for serotypes 2,3,4, and there was hyper-endemic
DENV-1 circulation. In April 2019, a DENV-2 outbreak was declared, the first since 1997 (Aubry et al., 2019).
Figure 1 continued on next page
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In order to assess whether the decline in ZIKV seroprevalence was also observed for other circu-
lating Flaviviruses, the MIA seroprevalence pattern against each of the four DENV serotypes was
analyzed in both countries, by age group (Figure 1—figure supplements 1–4). In Fiji, seropreva-
lence for DENV-1, DENV-2 and DENV-4 increased in participants in both age groups between 2013
and 2017 (Figure 1—figure supplements 1, 2 and 4). DENV-3 seroprevalence also increased in
both age groups between 2013 and 2015 following an outbreak in 2013–14 (Kucharski et al.,
2018a) and then declined in 2017 from 44% (32–57%) to 40% (28–52%) in children (McNemar’s test,
p=0.6) and from 59% (50–68%) to 49% (40–58%) in adults (McNemar’s test, p=0.01) (Figure 1—fig-
ure supplement 3). In French Polynesia between 2014 and 2018, seroprevalence in children aged
under 16 years showed no evidence of a change for DENV-1 and DENV-2 (chi-squared test,
p=0.1917 and p=1, respectively) (Figure 1—figure supplements 1–2) and decreased for DENV-3
and DENV-4 (chi-squared test, p<0.0001 and p=0.0085, respectively) (Figure 1—figure supple-
ments 3–4). In adult participants from the general population, seroprevalence for all four DENV
serotypes declined between 2014 and 2015.
The age-adjusted values for seroprevalence by MIA for the four DENV serotypes were similar to
the raw values (Table 2), suggesting that the decline in French Polynesia could not be explained by
differences in sampling by age. However, a higher proportion of the samples in 2014 tested positive
by MIA for all four DENV serotypes (Table 4), suggesting that the sampling included a group at
higher risk for arbovirus infection than those sampled in 2015. To check that the estimated decline in
ZIKV seroprevalence was not an artefact of this sampling bias, we re-estimated seroprevalence for
the four DENV serotypes and ZIKV using a bootstrap sample of the 2014 responses, with replace-
ment, weighted by the DENV exposure profile (excluding the virus of interest) in the 2015 survey so
that the bootstrap sample of the 2014 responses had a similar DENV exposure profile as in the 2015
responses. For example, when generating bootstrap estimates for DENV-1 in 2014, we resampled
participants based on the distribution of number of exposures to DENV-2, DENV-3, and DENV-4 in
the 2015 data (Table 5). After adjusting for prior exposure, there was no significant decline in sero-
prevalence for DENV-1, DENV-3, or DENV-4, which had all circulated in the five years preceding the
2014 data collection, whereas the decline in ZIKV was still present (chi-squared test, p=0.0047).
To explore dynamics of antibody waning at the individual level, we performed neutralization
assays (NT) on a subset of 45 participants from Fiji for whom sufficient sera were available to test
against ZIKV from all three collection periods, focusing on those who were seropositive to ZIKV by
MIA in 2013 or 2015. We found that in the 31 individuals who were ZIKV seronegative by NT (i.e. log
titre <2) in 2013 and had a rise in log titre 2 against ZIKV between 2013 and 2015, anti-ZIKV anti-
body responses waned significantly in 2017, with an average decline in log titre of  1.94 (t-test,
p<0.0001) (Figure 2A and Table 6). In total, four participants seroreverted between 2015 and 2017;
Figure 1 continued
The online version of this article includes the following figure supplement(s) for figure 1:
Figure supplement 1. Seroprevalence against DENV-1 in Fiji and French Polynesia, by age group.
Figure supplement 2. Seroprevalence against DENV-2 in Fiji and French Polynesia, by age group.
Figure supplement 3. Seroprevalence against DENV-3 in Fiji and French Polynesia, by age group.
Figure supplement 4. Seroprevalence against DENV-4 in Fiji and French Polynesia, by age group.
Table 2. Age-adjusted seroprevalence by MIA in participants aged over 16 in the general population of the Society Islands in French
Polynesia, based on serosurveys conducted in 2014 (n = 48) and 2015 (n = 672).
Virus 2014 seroprevalence (95% CI) 2014 age-adjusted seroprevalence (95% CI) 2015 seroprevalence (95% CI) 2015 age-adjusted (95% CI)
DENV1 85 (72–94) 83 (55–100) 80 (77–83) 80 (71–91)
DENV2 48 (33–62) 50 (28–87) 19 (16–22) 21 (15–21)
DENV3 75 (60–86) 72 (47–100) 56 (52–60) 55 (48–64)
DENV4 63 (47–76) 65 (40–100) 42 (38–46) 45 (38–54)
ZIKV 35 (22–50) 32 (16–62) 21 (18–25) 26 (20–34)
*chi-squared test comparing 2014 bootstrap estimates with 2015 results.
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all had a log titre of 4 against ZIKV in 2015. We observed a similar effect when we analysed all partic-
ipants who had a rise in log titre of at least 2 between 2013–15, regardless of serostatus in 2013
(Figure 2—figure supplement 1).
To test whether the dynamics of anti-ZIKV antibody waning were different from the responses to
DENV infection, we compared results for ZIKV to the neutralization response following a DENV-3
infection in the same cohort from Fiji. There was a large DENV-3 epidemic during 2013–14 in Fiji
(Osuna et al., 2016), which meant most seroconversions to DENV-3 occurred between the collection
of samples in 2013 and 2015. In those individuals that seroconverted to DENV-3 (n = 19) or ZIKV
(n = 31) between 2013 and 2015, the initial rise in NT log titres against ZIKV was larger than for
DENV-3, with a mean change of 5.0 and 3.37 respectively (Figure 2B and Table 6). All individuals
who had seroconverted to DENV-3 remained seropositive to the virus in 2017, while four individuals
who had seroconverted to ZIKV were seronegative in 2017. Although the NT log titres increased by
a mean of 0.89 for DENV-3 between 2015 and 2017 (two-sided t-test, p=0.04), log titres against
ZIKV declined by a mean of 1.94 over the same period (two-sided t-test, p<0.001) (Figure 2A and
Table 6).
In Fiji, there was a delay of around 18 months between the end of the 2013–14 DENV-3 epidemic
and collection of samples in 2015. As DENV titres can wane following infection, particularly in indi-
viduals with a prior DENV exposure (Clapham et al., 2016), titres against DENV-3 in Fiji may
Table 3. Detection of IgG by MIA against ZIKV in the paired samples from participants aged under
and over 16 years recruited during October-November 2015 and June 2017 in the Central division in
Fiji (n = 189).
Age groups are defined using age of participants when recruited to the study in 2013.
2015
2017
16 years >16 years Total participants
ZIKV+ ZIKV- ZIKV+ ZIKV- ZIKV+ ZIKV-
16 years
ZIKV+ 10 5 -- -- -- --
ZIKV- 4 48 -- -- -- --
>16 years
ZIKV+ -- -- 7 23 -- --
ZIKV- -- -- 2 90 -- --
Total Participants
ZIKV+ -- -- -- -- 17 28
ZIKV- -- -- -- -- 6 138
Table 4. Age distribution and profile of DENV exposure history in two cross-sectional surveys conducted in the general population
from the Society Islands, French Polynesia, in 2014 and 2015.
While the age distribution is similar in both studies, the sample in 2014 has a higher proportion of individuals who have tested positive
for infection from all four DENV serotypes by MIA.
Variable 2014 (n = 49) 2015 (n = 700)
Age distribution (median [IQR]) 47 [29-56] 43 [29-57]
Number of DENV serotypes positive at time of sample collection (n [%])
0 3 [0.061] 118 [0.17]
1 6 [0.12] 163 [0.23]
2 11 [0.22] 159 [0.23]
3 11 [0.22] 154 [0.22]
4 18 [0.37] 106 [0.15]
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therefore have had more time to wane and reach a stable persistent level than titres against ZIKV,
which may have circulated later than DENV-3. We therefore analysed changes in titre for participants
who were initially seronegative to DENV-1 and DENV-2, which were circulating at low levels in Fiji
between the two serological surveys in 2013 and 2015 (Figure 1). As with DENV-3, we found no evi-
dence of a subsequent overall decline during 2015–17 for those participants who seroconverted to
DENV-1 or DENV-2 during 2013–15 (Figure 2—figure supplement 2).
Of the 45 participants tested by neutralization assay, nine were initially seropositive to ZIKV by
NT in 2013. Fitting a generalized additive model to these data, we found that higher baseline mean
NT log titres against DENV were associated with an increased probability of seropositivity to ZIKV
(Figure 3A). In contrast, higher baseline mean DENV titres were not associated with increased sero-
positivity by MIA in 2013. There was little difference between the assay results in the 2015 samples
(Figure 3B), but we did find evidence of a difference in the 2017 results, with 15/45 participants pos-
itive by MIA and 31/45 positive by NT. This difference was associated with participants’ 2013 DENV
titres: those with intermediate DENV titres in 2013 had a significantly lower probability of being
seropositive in the MIA in 2017 compared to NT (Figure 3C).
Discussion
Analyzing data from serological surveys conducted in French Polynesia and Fiji at different time
points after the first reported autochthonous ZIKV transmission, we found evidence of a decline in
ZIKV seroprevalence. The high number of participants from the Fijian cohort that seroreverted
between 2015 and 2017 suggested that anti-ZIKV antibody levels waned in these individuals to the
point that they were no longer detectable by MIA. Using a neutralization assay to test longitudinal
sera collected in Fiji, we found that the mean change in neutralizing antibody titres against ZIKV also
decreased significantly between 2015 and 2017, showing that individual-level antibody titres against
ZIKV as well as overall seroprevalence decreased over time. In contrast, over the same period, neu-
tralizing antibody titres against DENV-3, a closely related Flavivirus which caused a large epidemic in
Fiji in 2013–2014 (Kucharski et al., 2018a), remained stable.
In both countries we found seroprevalence against ZIKV in individuals aged over 16 declined over
the two-year period following an outbreak, while the overall level of seroprevalence persisted in chil-
dren. This pattern was unique to ZIKV compared to DENV in both countries. It is possible that this is
related to the DENV immunological profile of individuals, given that the older population is likely to
have experienced more DENV infections over their lifetime. If an individual has experienced prior
DENV infections, high numbers of weakly neutralizing cross-reactive B cells may outcompete naı¨ve B
cells for ZIKV antigen (Midgley et al., 2011), leading to a short-term boost in antibody response
Table 5. Bootstrap estimated seroprevalence for each of the four DENV serotypes and ZIKV adjusted for sampling bias in two cross-
sectional surveys conducted in the general population from the Society Islands, French Polynesia, in 2014 and 2015.
Results from the cross-sectional surveys in the Society Islands, French Polynesia, in 2014 and 2015 show a decline in seroprevalence by
MIA against all 4 DENV serotypes and ZIKV. However, the 2014 sample included more individuals that tested positive for >1 DENV
serotype and are assumed to be a higher risk group. We used a bootstrap method with 10,000 iterations which estimated seropreva-
lence from a sample of the 2014 dataset, taken with replacement, weighted by the exposure distribution to other DENV viruses in the
2015 survey. After adjusting for the sample bias, there was no evidence of a decline in seroprevalence for DENV-1, DENV-3, or DENV-
4, which had circulated in the years preceding the 2014 sample collection (World Health Organisation, 2019), but there remained
strong evidence that ZIKV seroprevalence declined between 2014–15.
Virus
2014 seroprevalence (95% CI)
(n = 49) 2014 bootstrap estimates of seroprevalence (95% CI)
2015 seroprevalence (95% CI)
(n = 700) p-value*
DENV1 86 (73–94) 74 (61–86) 80 (77–83) 0.36
DENV2 47 (33–62) 38 (24–53) 18 (15–21) 0.0008
DENV3 76 (61–87) 64 (51–78) 55 (51–59) 0.21
DENV4 63 (48–77) 50 (37–65) 42 (38–46) 0.42
ZIKV 37 (23–52) 42 (29–55) 22 (19–25) 0.0047
*chi-squared test comparing 2014 bootstrap estimates with 2015 results.
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Figure 2. Waning of neutralizing antibody responses against ZIKV and DENV-3 in Fiji for participants who were seronegative to each virus in 2013 and
seroconverted in 2015. (A) Histogram of change in neutralization assay log titre against DENV-3 (n = 19) and ZIKV (n = 31) between 2015–2017 for
individuals who seroconverted to these respective viruses between 2013–2015 (i.e. log titre < 2 in 2013 and log titre  2 in 2015). (B) Histogram of
change in log titre against DENV-3 and ZIKV for individuals who seroconverted to these respective viruses during 2013–2015.
The online version of this article includes the following figure supplement(s) for figure 2:
Figure supplement 1. Waning of neutralizing antibody responses against ZIKV and DENV-3 in Fiji for participants who had a four-fold rise between
2013 and 2015.
Figure 2 continued on next page
Henderson et al. eLife 2020;9:e48460. DOI: https://doi.org/10.7554/eLife.48460 8 of 17
Research article Epidemiology and Global Health Microbiology and Infectious Disease
against ZIKV following ZIKV infection (Robbiani et al., 2017) but not a persistent specific response;
a similar phenomenon has been observed for other antigenically variable viruses like influenza
(Kucharski et al., 2018b). In the 2017 samples, more participants remained seropositive in the neu-
tralization assay – which measures the overall ability of sera to neutralize ZIKV – than in the MIA,
which tests for IgG antibodies against domain III of the envelope glycoprotein. This difference was
greatest for participants who had intermediate baseline titres to DENV in 2013 (Figure 3C), which
would support the hypothesis that prior DENV exposure may result in a detectable short-term spe-
cific response against ZIKV following ZIKV infection (as measured by MIA), but not a persistent spe-
cific response.
To our knowledge, the only other study to date that has investigated the long-term persistence
of neutralizing antibodies against ZIKV was conducted in 62 residents of Miami (Florida, USA), who
had a confirmed ZIKV infection in 2016 (Griffin et al., 2019). This cross-sectional study found that all
participants had neutralizing antibodies against ZIKV 12–19 months after infection. This study also
found that at least 37% of the participants had no evidence of past DENV infection, which is consis-
tent with the hypothesis that anti-ZIKV immune responses may persist longer in populations that
have had less exposure to DENV. More data are therefore needed to test hypotheses about the
potential impact of pre-existing anti-DENV immune response on anti-ZIKV antibody waning.
Although we found evidence of a decline in seroprevalence for antibodies against domain III of
the envelope glycoprotein, as well as waning neutralizing antibody responses following two ZIKV
outbreaks, the implications for susceptibility to future ZIKV infection remain unclear. Given the anti-
genic similarity of DENV and ZIKV (Priyamvada et al., 2016), it is commonly assumed that the
immune response to ZIKV infection will be similar to that following DENV infection. High levels of
neutralizing antibodies to DENV have been shown to correlate with protection from symptomatic
infection (Katzelnick et al., 2016). Moreover, infection with a single DENV serotype can confer life-
long immunity to the infecting serotype as well as a transient period of cross-neutralization against
heterologous serotypes (Wahala and Silva, 2011). However, it is unclear in the context of ZIKV what
the relationship is between a specific titre value and susceptibility to further infection. A key aim for
future work will be to establish how waning antibody levels as measured by MIA and neutralization
assays may impact protective immunity, and hence susceptibility to reinfection in populations that
have already experienced transmission of ZIKV.
There are some additional limitations to our analysis. First, we did not have reverse transcription
polymerase chain reaction (RT-PCR) confirmation of ZIKV infection in individuals sampled in this
study. We have presented analysis of representative serological surveys in two locations with known,
RT-PCR-confirmed ZIKV outbreaks (Mallet et al., 2015; World Health Organisation, 2015). How-
ever, RT-PCR confirmation for ZIKV at the individual level remains difficult to obtain, in particular
Figure 2 continued
Figure supplement 2. Waning of neutralizing antibody responses against DENV-1 and DENV-2 in Fiji for participants who were seronegative in 2013
and seroconverted in 2015.
Table 6. Change in neutralization titre between 2013–2017 in a cohort of 45 study participants in
Fiji.
ZIKV and DENV-3 both circulated in Fiji between the collection of samples in 2013 and 2015, with
ZIKV first reported in July 2015 and DENV-3 circulating between October 2013 and January 2015.
Neutralization titre levels rose significantly over this period. Between 2015 and 2017, DENV-3 titre lev-
els still increased with a mean change in tire of 0.89. By contrast, the mean change in ZIKV titre over
this period decreased ( 1.9).
Virus
2013–2015 change,
Mean [95% CI] p-value*
2015–2017 change,
Mean [95% CI] p-value*
ZIKV (n=31) 5 [4.5, 5.5] <0.0001  1.9 [-2.4,–1.5] <0.0001
DENV3 (n=19) 3.4 [2.9, 3.9] 0.89 [0.046, 1.7]
* t-test comparing change in neutralization titre for ZIKV and DENV-3 between 2013–2015, and 2015–2017.
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from blood samples, and there have been relatively few confirmations globally compared to the
number of suspected cases (Ferguson et al., 2016), let alone analysis of long-term antibody dynam-
ics in RT-PCR confirmed patients. In French Polynesia, there were approximately 32,000 reported
clinical cases of ZIKV infection, but only 297 documented RT-PCR-confirmed cases (Mallet et al.,
2015). As a result, antibody responses in RT-PCR-confirmed cases may not necessarily be represen-
tative of immune responses against ZIKV in the wider population, particularly following asymptom-
atic infection. Although MIA seropositivity in our study was defined using control sera collected over
a year after RT-PCR-confirmed infection, our results suggest that this threshold may not detect long-
term waning responses in individuals who had unreported, and likely less severe, infections.
Our analysis was also limited by study design. In French Polynesia, surveys were cross-sectional,
so we were unable to examine temporal antibody dynamics at the individual level. However, both
cross-sectional studies of the general population were conducted using population representative
cluster sampling (Aubry et al., 2017) in the same remote island locations with stable population
composition, which enabled robust comparisons of overall seroprevalence. We did identify one
potential source of sampling bias with different DENV exposure profiles in the two surveys, but our
conclusions of declining seroprevalence for ZIKV persisted once we adjusted for this bias. We also
used a different serological testing method between the studies in French Polynesia in 2014 and
2015. However, both used the same recombinant antigens and it has been shown that there was
good agreement between ELISA and MIA in the 2014 samples (see Materials and methods). In Fiji, a
strength of our study was the collection of longitudinal samples from the same individuals at three
time points. However, our sample size was limited given the logistical challenge of recontacting par-
ticipants twice over a four-year period. These data provided strong evidence that ZIKV seropreva-
lence declined over the two-year period following first reports of circulation, but our sample size
was insufficient to fully explore the potential effect of anti-DENV pre-existing immunity on anti-ZIKV
antibody waning once we stratified individuals by previous DENV exposure. Although the outbreaks
of DENV-3 in Fiji and ZIKV in French Polynesia were well-documented and occurred over a relatively
brief period of time (Figure 1), it was harder to identify the likely time of infection for other viruses –
such as ZIKV in Fiji or DENV in French Polynesia – in our study populations. Several participants in
Fiji were seropositive to ZIKV by neutralization assay (NT) in 2013, but this result may be influenced
by cross-reaction; participants who had high pre-existing titres to DENV in 2013 were more likely to
be seropositive by NT (Figure 3A). In our main analysis of titre dynamics, we therefore focused on
the subset of participants who were seronegative by NT in 2013 (Figure 2). However, we obtained
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Figure 3. Relationship between mean DENV log neutralization titre across the four serotypes in 2013 and ZIKV seroprevalence using different assays, in
a subset of 45 participants. (A) Seroprevalence by MIA, shown in grey, and neutralization test (NT), shown in orange, for sera collected in 2013. Line
shows prediction from GAM fitted to each dataset, with shaded region showing 95% CI, and points show raw data. (B) Seroprevalence for sera
collected from the same participants in 2015. (C) Seroprevalence for sera collected from the same participants in 2017.
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the same conclusion when participants who were initially seropositive were also considered (Fig-
ure 2—figure supplement 1).
The global ZIKV epidemic began in the Pacific islands in 2013 before spreading in Central and
South America from 2015. Seroprevalence studies following ZIKV epidemics in Latin America have
been reported but data have either been non-representative (Netto et al., 2017) or not enough
time had elapsed since the outbreak to observe long-term dynamics (Rodriguez-Barraquer et al.,
2019; Zambrana et al., 2018). To our knowledge, these are the first studies of community seroprev-
alence over a long-term period following a ZIKV outbreak. Therefore, patterns observed in Pacific
islands may be an early indication of what might happen to seroprevalence in Latin America where
ZIKV outbreaks began two to three years after the French Polynesia epidemic (Cao-Lormeau et al.,
2014; Bogoch et al., 2016).
In the short-term, our findings have implications for the design of follow up studies of ZIKV. Our
results provide evidence that levels of seroprevalence one to two years following ZIKV circulation
may be lower than previously expected and study designs may need to be adapted to reflect this,
particularly in settings that exhibit long-term low level circulation of ZIKV as opposed to large spo-
radic outbreaks (Ruchusatsawat et al., 2019). For example, estimates of microcephaly risk may be
inflated if derived from long-term seroprevalence data that underestimate the true extent of infec-
tion within the population, and results of clinical trials could also be biased if post-outbreak sero-
prevalence is used an indicator of infection within a population (Cohen, 2018). In the longer-term,
our results demonstrate the value of longitudinal serological studies of flaviviruses, and analysis using
multiple serological tests, including neutralization assays (Clapham et al., 2016). Such studies will be
essential to understand different aspects of the short and long-term immune antibody response
against ZIKV, and how prior exposures to DENV may influence these responses.
Materials and methods
Study location and participants
French polynesia
Four separate ZIKV serosurveys were previously conducted in the Society Islands (Table 1). As
reported previously (Aubry et al., 2017; Aubry et al., 2015a), a first serosurvey (n = 593) was con-
ducted in adult blood donors recruited between July 2011 and October 2013, before the ZIKV out-
break that occurred between October 2013 and April 2014 (Cao-Lormeau et al., 2014). Two
population-representative serosurveys were conducted among the general population, firstly
between February and March 2014 (n = 196), and then between September and November 2015
(n = 700). The two studies in the general population both spanned a range of adult age groups
(Table 7). An additional serosurvey was conducted among schoolchildren between May and June
2014 (n = 476). Finally, a fifth serosurvey was conducted among schoolchildren in the Society Islands
in June 2018 (n = 457) using the same protocol as in 2014 (Aubry et al., 2017).
Fiji
Three serosurveys were conducted in Fiji (Table 1). Individuals were first recruited into a population-
representative community-based typhoid/leptospirosis seroprevalence study between September
and November 2013 (Watson et al., 2017) (n = 1,787), before autochthonous transmission of ZIKV
was first detected in July 2015 (World Health Organisation, 2015). Briefly, nursing zones were ran-
domly selected, from which one individual from 25 households in a randomly selected community
was recruited. Participants who had consented to being contacted again for health research were
subsequently recruited in November 2015 in 23 communities in Central Division through last known
addresses, phone numbers and the assistance of local nurses (n = 327) (Kama et al., 2019). A third
follow-up serosurvey was conducted in June 2017 using the same protocol as in 2015 (n = 321)
(Kucharski et al., 2018a). Follow-up surveys were only performed in Central Division, which was the
focus of a DENV-3 outbreak in 2013–14 (Kucharski et al., 2018a). Only blood samples serially col-
lected from the same participants (n = 189) in 2013, 2015 and 2017 were analyzed in the main results
presented in this study.
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Informed consent and ethics approvals
French polynesia
The five serosurveys were approved by the Ethics Committee of French Polynesia (ref 61/CEPF 08/
29/2013, 60/CEPF 06/27/2013, 74/CEPF 05/04/2018, and 75/CEPF 05/04/2018).
Fiji
The original 2013 study, and the 2015 and 2017 follow up studies were approved by the Fiji National
Research Ethics Review Committee (ref 2013–03, 2015.111.C.D, 2017.20.MC) and the London
School of Hygiene and Tropical Medicine Observational Research Ethics Committee (ref 6344,
10207, 12037).
Serological analysis
French polynesia
Serum samples collected from blood donors between July 2011 and October 2013 and samples col-
lected from the general population and schoolchildren in 2014 were all tested for presence of IgG
antibodies against ZIKV and each of the four DENV serotypes using a recombinant antigen-based
indirect ELISA as reported previously (Aubry et al., 2017; Aubry et al., 2015a). Samples collected
from the general population in 2015 and from schoolchildren in 2018 were tested by microsphere
immunoassay (MIA) using the same recombinant antigens as for the ELISA (Cao-Lormeau et al.,
2016; Aubry et al., 2017; Kama et al., 2019). Recombinant antigens used in both assays comprised
domain III of the envelope glycoprotein of ZIKV, DENV-1, DENV-2, DENV-3, or DENV-4 strains
(respective GenBank accession no. KJ776791, AF226686.1, FM986654, FJ44740.1, FM986672.1) and
were produced using the Drosophila S2 expression system (Life Technologies, USA) as previously
detailed (Aubry et al., 2015b). Serostatus was defined by a cut-off determined using positive and
negative control sera analyzed by ROC curve. The sensitivity and specificity of the MIA assay were
respectively 100% and 100% for DENV-1, 89.5% and 97.1% for DENV-2, 100% and 100% for DENV-
3, 96.9% and 100% for DENV-4, and 79.6% and 94.9% for ZIKV. The positive control sera for ZIKV
was collected 13 months after RT-PCR confirmed infection. In the serosurvey conducted among the
general population of the five archipelagos in French Polynesia in 2014 (Aubry et al., 2017), 196
samples were tested using both ELISA and MIA: among the 97 serum samples that tested positive
for anti-ZIKV IgG by ELISA, 78 (80%) were also found positive by MIA; and among the 99 serum sam-
ples that tested negative for anti-ZIKV IgG by ELISA, 70 (71%) were also found negative by MIA.
This produced a value of Cohen’s k = 0.51 (Aubry et al., 2017).
Table 7. Age distribution of study population in French Polynesia.
Overall population distribution shown, along with total samples collected in each age group in 2014
and 2015 serosurveys.
Age range Population estimate (2017) Samples in 2014 study Samples in 2015 study
0–9 42,770 0 0
10–19 43,705 3 22
20–29 48,914 10 135
30–39 42,144 5 131
40–49 40,886 8 119
50–59 34,478 15 128
60–69 21,099 2 85
70–79 10,481 5 46
80–89 3773 0 9
90+ 416 0 0
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Fiji
All serum samples collected in Fiji were tested using MIA to detect IgG antibodies against ZIKV and
all four DENV serotypes as previously reported (Cao-Lormeau et al., 2016; Aubry et al., 2017;
Kucharski et al., 2018a). To follow the evolution of antibody titres at the individual level, a subset of
samples collected from the same individuals in 2013, 2015 and 2017 were tested for the presence of
neutralizing antibodies against ZIKV and each of the four DENV serotypes using a neutralization
assay as previously described (Cao-Lormeau et al., 2016). This subset of samples was selected to
include all participants who were seropositive to ZIKV by MIA in 2013 and 2015, as well as one par-
ticipant just below the seropositivity threshold, and for whom we had sufficient longitudinal serum
available from 2013, 2015 and 2017 to test by neutralization assay (n = 45). We also tested samples
from an additional 24 participants from the same cohort who were seropositive to ZIKV by MIA in
2013 or 2015 and for whom we had sufficient serum from 2013 and 2015 to test by neutralization
assay, but no matched sample from the 2017 follow up survey (i.e. 69 paired samples in total). ZIKV
log titres in the neutralization assay followed a bimodal distribution, which supported the use of a
log titre of 2 as a cutoff for seropositivity (Figure 4).
Of the 9/45 participants with three samples who were seropositive to ZIKV by neutralization assay
in 2013, all were seropositive to at least one DENV serotype (Figure 4—figure supplement 1). To
assess the potential for cross-reactive antibody responses, we examined the correlation between
changes in log titre to different viruses between 2013 and 2015. Among the 20/69 paired samples
that tested seronegative against all five viruses in 2013 and were re-tested in 2015, there was no evi-
dence of an association between changes in ZIKV titre and changes in titre against any of the DENV
serotypes, suggesting that the changes in ZIKV titre were unlikely to be strongly influenced by
DENV cross-reaction (Figure 4—figure supplement 2). However, the 49/69 participants who had a
pre-2013 DENV exposure and a large rise against ZIKV between 2013–15 tended to exhibit a smaller
rise against DENV viruses (Figure 4—figure supplement 3).
A previous study, which tested serological samples from Fiji across three divisions (Kama et al.,
2019), found that of the samples reactive by MIA, 66/83 (79.5%) exhibited neutralizing activity for
ZIKV (k = 0.71) and 109/112 (97.3%) for DENV (k = 0.80). In this study, we tested what proportion of
samples for the 45 participants in the full dataset (i.e. 135 samples in total) that were seropositive or
seronegative by MIA had the same result by the neutralization assay. We found that 54/68 (79.4%)
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Figure 4. Distribution of ZIKV neutralization titres in the Fiji serosurveys. Results shown for 45 participants who had samples available from 2013, 2015,
and 2017. Dashed line shows the threshold used to define seropositivity.
The online version of this article includes the following figure supplement(s) for figure 4:
Figure supplement 1. Individual-level neutralization log titres against the four DENV serotypes and ZIKV in Fiji.
Figure supplement 2. Correlation between rise in DENV and ZIKV neutralization log titres between 2013–2015 for participants who were initially
seronegative (i.e. log titre <2) to all five viruses in 2013 (n = 20).
Figure supplement 3. Correlation between change in DENV and ZIKV log titres between 2013–2015 for participants who were initially seropositive (i.
e. log titre 2) to at least one DENV virus in 2013 (n = 49).
Henderson et al. eLife 2020;9:e48460. DOI: https://doi.org/10.7554/eLife.48460 13 of 17
Research article Epidemiology and Global Health Microbiology and Infectious Disease
samples that were positive to ZIKV by MIA were also positive in the neutralization assay, and 42/67
(62.7%) who were seronegative were also negative by neutralization assay (k = 0.42). We also calcu-
lated the proportion positive by neutralization assay that had the same result by MIA. We found that
54/79 (68.4%) samples that were positive to ZIKV in the neutralization assay were also positive by
MIA, and 42/56 (75%) who were seronegative were also negative by MIA.
Statistical analysis
For data from Fiji, where serial samples were collected from the same individual, changes in sero-
prevalence between studies were tested using McNemar’s test. In French Polynesia, chi-squared
tests were performed to test for evidence of a change in seroprevalence between two cross-sec-
tional surveys. Changes in mean log titre between groups were analyzed using a t-test. To analyse
the potentially non-linear relationship between DENV neutralization titres and seroprevalence by
MIA and neutralization test (Figure 3), we used a generalized additive model via the mcgv package
in R (Wood, 2019). The model was of the form g(E(y))=b + f(x), where y was the binary outcome var-
iable, x was the predictor (i.e. titre), g was the link function, b was the intercept, and f was a smooth
function represented by a penalized regression spline. Mean DENV titre was calculated as the mean
of log titres against the four DENV serotypes for each participant. All data and code used in the
analysis are available at: https://github.com/a-henderson91/zika-sero-pacific/ (Henderson and
Kucharski, 2019; copy archived at https://github.com/elifesciences-publications/zika-sero-pacific/
settings).
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